

Financial news for DRRX dated on 2020-05-27: HC Wainwright & Co. Maintains Buy on Durect, Raises Price Target to \$6

Financial news for DRRX dated on 2020-05-13: 84 Biggest Movers From Yesterday

Financial news for DRRX dated on 2020-05-12: 60 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRRX dated on 2020-05-11: Durect Q1 EPS \$(0.050) Misses \$(0.040) Estimate, Sales \$2.800M May Not Compare To \$7.190M Estimate

Financial news for DRRX dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for DRRX dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for DRRX dated on 2020-03-05: 92 Biggest Movers From Yesterday

Financial news for DRRX dated on 2020-03-04: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for DRRX dated on 2020-03-04: DURECT shares are trading higher after the company reported better-than-expected Q4 sales results.

Financial news for DRRX dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for DRRX dated on 2020-03-04: 38 Stocks Moving in Wednesday's Pre-Market Session

Financial news for DRRX dated on 2020-03-03: 10 Stocks Moving In Tuesday's After-Hours Session

Financial news for DRRX dated on 2020-03-03: DURECT shares are trading higher after the company reported better-than-expected Q4 sales results.

Financial news for DRRX dated on 2020-03-03: CORRECTION: Synacor Sees Q1 Sales \$21.5M-\$23.5M vs \$24.8M Estimate; FY20 Sales \$95M-\$102M vs \$100.1M Est.; Initial Headline Was Posted With Ticker DRRX; This Was An Error

Financial news for DRRX dated on 2020-03-03: Durect Q4 EPS \$(0.02), Inline, Sales \$26.8M Beat \$10.91M Estimate

Financial news for DRRX dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for DRRX dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for DRRX dated on 2020-02-21: Durect shares are trading higher. Not seeing any news to justify the price action.

Financial news for DRRX dated on 2020-02-11: Durect shares are trading higher. Not seeing any company-specific news to justify the price action.

Financial news for DRRX dated on 2020-01-31: B. Riley Initiates Coverage On Durect with Buy Rating, Announces \$5 Price Target

Financial news for DRRX dated on 2020-01-31: 70 Biggest Movers From Yesterday

Financial news for DRRX dated on 2020-01-27: 4 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's After-Market Session

Financial news for DRRX dated on 2020-01-27: 36 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for DRRX dated on 2020-01-27: 20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session

Financial news for DRRX dated on 2020-01-22: 82 Biggest Movers From Yesterday

Financial news for DRRX dated on 2020-01-21: 5 Drug Manufacturers--Specialty & Generic Stocks Moving In Tuesday's After-Market Session

Financial news for DRRX dated on 2020-01-21: 29 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for DRRX dated on 2020-01-21: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRRX dated on 2020-01-21: Durect shares are trading lower in sympathy with the broader market as anxiety around the coronavirus outbreak in China spreads to global markets. NOTE: An FDA AdCom panel voted to discuss an NDA for POSIMIR, 6 voted for, and 6 voted against

Financial news for DRRX dated on 2020-01-17: 38 Stocks Moving In Friday's Mid-Day Session

Financial news for DRRX dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for DRRX dated on 2020-01-17: DURECT Shares To Resume Trade At 7:15 a.m. EST

Financial news for DRRX dated on 2020-01-17: DURECT Reports FDA Anesthetic and Analgesic Drug Products Advisory Committee Met Thurs. To Discuss Class 2 New Drug Application for POSIMIR; 6 AdCom Members Voted To Recommend Efficacy, Safety, 6 Voted Against Recommendation

Financial news for DRRX dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for DRRX dated on 2020-01-16: DURECT Issues Press Release Highlighting Halt In Stock Ahead Of FDA AdCom Panel To Discuss POSIMIR For Post-Surgical Analgesia

Financial news for DRRX dated on 2020-01-16: DURECT Shares Halted News Pending

Financial news for DRRX dated on 2020-01-15: Durect shares are trading higher. The stock moved higher following unusual interest in next month's \$2.5 call contract.

Financial news for DRRX dated on 2020-01-15: Durect Option Alert: Feb 21 \$2.5 Calls at the Ask: 600 @ \$0.75 vs 1392 OI; Earnings 3/5 After Close [est] Ref=\$2.5

Financial news for DRRX dated on 2020-01-15: 34 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for DRRX dated on 2020-01-12: The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO

Financial news for DRRX dated on 2020-01-09: Durect shares are trading lower. Not seeing any company-specific news to justify the price action.

Financial news for DRRX dated on 2020-01-06: 53 Biggest Movers From Friday

Financial news for DRRX dated on 2020-01-03: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for DRRX dated on 2020-01-03: 65 Biggest Movers From Yesterday

Financial news for DRRX dated on 2020-01-02: Mid-Afternoon Market Update: Signet Jewelers Falls Following Wells Fargo Downgrade; Trillium Therapeutics Shares Surge

Financial news for DRRX dated on 2020-01-02: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for DRRX dated on 2020-01-02: Mid-Day Market Update: Dow Rises 170 Points; Synthesis Energy Systems Shares Jump

Financial news for DRRX dated on 2020-01-02: Mid-Morning Market Update: Markets Open Higher; Imagination Technologies Signs New Deal With Apple

Financial news for DRRX dated on 2020-01-02: Durect shares are trading lower after the company announced DUR-928 did not demonstrate benefit over placebo in Phase 2a psoriasis trial. The company is discontinuing development.

Financial news for DRRX dated on 2020-01-02: DURECT Corporation Announces DUR-928 Did Not Demonstrate Benefit Over Placebo In Phase 2a Psoriasis Trial; Co. To Discontinue Development

Financial news for DRRX dated on 2020-01-02: The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

Financial news for DRRX dated on 2020-01-02: 63 Biggest Movers From Tuesday

Financial news for DRRX dated on 2020-01-01: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for DRRX dated on 2019-12-31: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRRX dated on 2019-12-30: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for DRRX dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for DRRX dated on 2019-12-27: Durect Option Alert: Jul 17 \$5 Puts Sweep (9) near the Bid: 500 @ \$2.5 vs 0 OI; Ref=\$3.109

Financial news for DRRX dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for DRRX dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for DRRX dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for DRRX dated on 2019-12-24: 78 Biggest Movers From Yesterday

Financial news for DRRX dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for DRRX dated on 2019-11-18: Cantor Fitzgerald Assumes Durect at Overweight, Announces \$5 Price Target

Financial news for DRRX dated on 2019-11-12: Durect Corporation Announces Results From Phase 2A Clinical Trial Of DUR-928 In Alcoholic Hepatitis Patients In A Late-breaking Presentation At The Liver Meeting; All Patients Treated With DUR-928 In Trial Survived 28-Day Follow-Up Period

Financial news for DRRX dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for DRRX dated on 2019-11-10: The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

Financial news for DRRX dated on 2019-11-04: Durect Q3 EPS \$(0.01) Misses \$0.02 Estimate, Sales \$10.8M Miss \$15.7M Estimate

Financial news for DRRX dated on 2019-10-21: DURECT Reports DUR-928 Phase 2a Study Results Selected For Late-Breaking Oral Presentation At 2019 The Liver Meeting

Financial news for DRRX dated on 2019-10-17: Durect shares are trading higher on seemingly no company-specific news.

Financial news for DRRX dated on 2019-10-07: DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

Financial news for DRRX dated on 2019-10-02: Durect shares are trading higher after the company announced the FDA Advisory Committee plans to meet to review POSIMIR for the treatment of post-surgical pain.

Financial news for DRRX dated on 2019-10-02: DURECT Announces FDA Advisory Committee Meeting To Review POSIMIR For The Treatment Of Post-Surgical Pain; Meeting Scheduled For Jan. 16

Financial news for DRRX dated on 2019-09-30: Durect Corp shares are trading lower likely on profit taking after the stock has seen continuous upward momentum over the last 30 days. Not seeing any news to justify the price action.

Financial news for DRRX dated on 2019-09-30: 52 Biggest Movers From Friday

Financial news for DRRX dated on 2019-09-27: Shares of small-cap drugmaker Durect are trading lower. Shares have rallied this month and are potentially selling off.

Financial news for DRRX dated on 2019-09-25: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., September 25, 2019

Financial news for DRRX dated on 2019-09-25: Durect shares are trading higher despite no company-specific news. The stock has rallied approximately 45% in the past month.

Financial news for DRRX dated on 2019-09-24: The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger

Financial news for DRRX dated on 2019-09-23: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Mon, September 23, 2019

Financial news for DRRX dated on 2019-09-23: Stocks That Hit 52-Week Highs On Monday

Financial news for DRRX dated on 2019-09-23: 34 Stocks Moving In Monday's Mid-Day Session

Financial news for DRRX dated on 2019-09-23: Durect shares are trading higher. Not seeing any news to justify the price action. The stock has seen continued upward momentum over the past 3 months.

Financial news for DRRX dated on 2019-09-20: Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Roku Shares Plummet

Financial news for DRRX dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for DRRX dated on 2019-09-20: Durect shares are trading higher. Not seeing any news to justify the price action.

Financial news for DRRX dated on 2019-09-18: 10 Biggest Price Target Changes For Wednesday

Financial news for DRRX dated on 2019-09-18: Stifel Nicolaus Maintains Hold on Durect, Raises Price Target to \$2.1

Financial news for DRRX dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for DRRX dated on 2019-09-18: Stifel Maintains Hold on Durect, Raises Price Target to \$2.1

Financial news for DRRX dated on 2019-09-17: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DRRX dated on 2019-09-17: Durect shares are trading higher after the company announced the completion of its Phase 2a Trial of DUR-928 for patients with alcoholic hepatitis.

Financial news for DRRX dated on 2019-09-17: DURECT Reports Completion Of Phase 2a Trial Of DUR-928 In Patients With Alcoholic Hepatitis

Financial news for DRRX dated on 2019-09-09: Stocks That Hit 52-Week Highs On Monday

Financial news for DRRX dated on 2019-09-09: 64 Biggest Movers From Friday

Financial news for DRRX dated on 2019-09-06: Stocks That Hit 52-Week Highs On Friday

Financial news for DRRX dated on 2019-09-06: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for DRRX dated on 2019-09-06: Benzinga's Top Upgrades, Downgrades For September 6, 2019

Financial news for DRRX dated on 2019-09-06: Durect shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a price target of \$5 per share.

Financial news for DRRX dated on 2019-09-06: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for DRRX dated on 2019-09-06: Cantor Fitzgerald Initiates Coverage On Durect with Overweight Rating, Announces \$5 Price Target

Financial news for DRRX dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for DRRX dated on 2019-08-27: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DRRX dated on 2019-08-27: The Daily Biotech Pulse: Nuvecra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO

Financial news for DRRX dated on 2019-08-26: Stocks That Hit 52-Week Highs On Monday

Financial news for DRRX dated on 2019-08-22: Durect shares are trading higher on seemingly no company-specific news.

Financial news for DRRX dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for DRRX dated on 2019-08-07: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 7, 2019

Financial news for DRRX dated on 2019-08-07: Shares of several healthcare companies are trading lower in sympathy with the overall market.

Financial news for DRRX dated on 2019-08-02: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019

Financial news for DRRX dated on 2019-08-01: Durect shares are trading lower after the company reported worse-than-expected Q2 sales results.

Financial news for DRRX dated on 2019-08-01: Durect Q2 EPS \$(0.04), Inline, Sales \$3.985M Miss \$4.02M Estimate

Financial news for DRRX dated on 2019-07-31: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., July 30, 2019

Financial news for DRRX dated on 2019-07-26: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for DRRX dated on 2019-07-23: Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Tue., July 23, 2019

Financial news for DRRX dated on 2019-07-23: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, July 23, 2019

Financial news for DRRX dated on 2019-07-23: 58 Biggest Movers From Yesterday

Financial news for DRRX dated on 2019-07-22: Mid-Afternoon Market Update: Peak Resorts Climbs Following Acquisition News; Cadence Bancorp Shares Plummet

Financial news for DRRX dated on 2019-07-22: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for DRRX dated on 2019-07-22: Durect shares are trading higher after the company and Gilead entered into a license agreement for long-acting Injectable HIV Investigational products. The company will receive \$25 million with the potential of obtaining up to \$75 million.

Financial news for DRRX dated on 2019-07-22: DURECT Soars On Out-Licensing Deal With Gilead For Up To \$170M

Financial news for DRRX dated on 2019-07-22: DURECT And Gilead Enter Into License Agreement For Long-Acting Injectable HIV Investigational Product; DURECT To Receive Upfront Payment Of \$25M With Potential For Up To \$75M In Development And Regulatory Milestones

Financial news for DRRX dated on 2019-07-17: DURECT Announces FDA Agreed To File Full Response To POSIMIR Complete Response Letter As Complete Class 2 Resubmission

Financial news for DRRX dated on 2019-06-27: DURECT Reports FDA Submission Of Full Response to PSIMIR Complete Response Letter

Financial news for DRRX dated on 2019-06-26: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Financial news for DRRX dated on 2019-06-25: DURECT Receives Approval From Nasdaq For Transfer Of Listing To Nasdaq Capital Market

Financial news for DRRX dated on 2019-06-18: DURECT Reports Completion Of 90 mg Severe Cohort, Dose Escalation Committee Approval To Commence 150 mg Dosing In Patients With Severe Alcoholic Hepatitis In Ongoing DUR-928 Phase 2a AH Trial

Financial news for DRRX dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for DRRX dated on 2019-05-07: Durect Q1 EPS \$(0.04) Beats \$(0.05) Estimate, Sales \$4.131M Beat \$3.5M Estimate

Financial news for DRRX dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for DRRX dated on 2019-03-27: DURECT Reports Patient Enrollment In Phase 1b Trial Of Oral DUR-928 In Patients with NASH

Financial news for DRRX dated on 2019-03-21: DURECT Reports Patient Dosing In Phase 2a Proof-Of-Concept Trial Of Topical DUR-928 In Patients With Mild To Moderate Plaque Psoriasis

Financial news for DRRX dated on 2019-03-07: Durect Q4 EPS \$(0.05), Inline, Sales \$3.627M Miss \$3.77M Estimate

Financial news for DRRX dated on 2019-03-07: Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

Financial news for DRRX dated on 2019-02-27: DURECT Announces Plans To Submit To FDA A Full Response To POSIMIR Complete Response Letter

Financial news for DRRX dated on 2019-01-07: DURECT shares are trading lower after the company announced it would discontinue its primary sclerosing colangitis trial.

Financial news for DRRX dated on 2019-01-07: DURECT to Discontinue its Primary Sclerosing Colangitis Trial

Financial news for DRRX dated on 2019-01-03: DURECT Corporation Announces Investor Call To Provide Corporate Update Scheduled For Jan. 7

Financial news for DRRX dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for DRRX dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for DRRX dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for DRRX dated on 2018-12-19: DURECT Highlights Commercial Launch Plans For PERSERIS ER Injectable Suspension For Treatment Of Schizophrenia In Adults

Financial news for DRRX dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for DRRX dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for DRRX dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for DRRX dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for DRRX dated on 2018-12-12: The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

Financial news for DRRX dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for DRRX dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for DRRX dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for DRRX dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for DRRX dated on 2018-11-21: Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Financial news for DRRX dated on 2018-11-21: The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

Financial news for DRRX dated on 2018-11-19: DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients

Financial news for DRRX dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for DRRX dated on 2018-11-07: Durect Q3 EPS \$(0.02), Inline, Sales

\$8.036M Miss \$8.57M Estimate

Financial news for DRRX dated on 2018-10-01: DURECT Announces Michael Arenberg CFO

Financial news for DRRX dated on 2018-09-18: DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization For ADHD In Taiwan

Financial news for DRRX dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for DRRX dated on 2018-08-06: FDA Decision Sends Pain Therapeutics Reeling

Financial news for DRRX dated on 2018-08-06: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for DRRX dated on 2018-08-06: Durect Corp shares are trading down 6.4% after the company's licensee Pain Therapeutics received CRL from FDA regarding REMOXY.

Financial news for DRRX dated on 2018-08-06: Pain Therapeutics Gets a Complete Response Letter From the FDA Stating, 'The Data Submitted in [the] NDA Do Not Support the Conclusion That the Benefits of [REMOXY] Extended-Release Capsules Outweigh the Risks'

Financial news for DRRX dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for DRRX dated on 2018-08-01: Durect Q2 EPS \$(0.04) Beats \$(0.06) Estimate, Sales \$3.413M Miss \$3.67M Estimate

Financial news for DRRX dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for DRRX dated on 2018-08-01: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Financial news for DRRX dated on 2018-07-30: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Jul. 30, 2018

Financial news for DRRX dated on 2018-07-30: DURECT Corp. Shares Jump Up 19% Premarket After FDA Approved New Drug Application For PERSERIS Schizophrenia Treatment, Triggering \$5M Payout To Co.

Financial news for DRRX dated on 2018-07-30: DURECT Announces FDA Approval of Indivior's PERSERIS Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

Financial news for DRRX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for DRRX dated on 2018-07-27: REMINDER: Durect Has FDA PDUFA Date For RBP-7000 Saturday July 28th

Financial news for DRRX dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for DRRX dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for DRRX dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for DRRX dated on 2018-06-30: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for DRRX dated on 2018-06-27: Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

Financial news for DRRX dated on 2018-06-26: Hearing Pain Therapeutics DURECT FDA Panel Voted Against Remoxy Approval In 3 For, 14 Against Approval

Financial news for DRRX dated on 2018-06-26: Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Financial news for DRRX dated on 2018-06-26: REMINDER: Pain Therapeutics and DURECT Have FDA AdCom Meeting For Remoxy Today BZ NOTE: A CRL Was Issued On Remoxy September 26th 2016

Financial news for DRRX dated on 2018-06-25: The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs

Financial news for DRRX dated on 2018-06-25: REMINDER Stocks With FDA Actions Expected This Week Include: Achaogen PDUFA Date for Plazomicin 6/25, Durect and Pain Therapeutics AdCom For Remoxy June 26, & GW Pharma PDUFA For Epidiolex in LG Syndrome June 27

Financial news for DRRX dated on 2018-06-24: The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Financial news for DRRX dated on 2018-06-01: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Financial news for DRRX dated on 2018-05-09: DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR, Co. Is Now eligible For Up To \$30M In Milestone Payments, Down From \$43M In Payments Before

Financial news for DRRX dated on 2018-05-02: Durect Q1 EPS \$(0.05) Beats \$(0.06) Estimate, Sales \$3.48M Miss \$4.2M Estimate

Financial news for DRRX dated on 2018-04-25: DURECT Reports Patient Dosing In Phase 2a Trial Of DUR-928 In Alcoholic Hepatitis

Financial news for DRRX dated on 2018-04-20: 32 Biggest Movers From Yesterday

Financial news for DRRX dated on 2018-03-20: DURECT Shares Up 6% After Co. Earlier Announced FDA Will Hold AdCom Meeting For Co.'s REMOXY ER, An Abuse-Deterrent, Extended Release Formulation Of Oxycodone, On Jun. 26

Financial news for DRRX dated on 2018-03-20: DURECT Reports FDA Panel Meeting For REMOXY ER Will Be Jun. 26, 2018; PDUFA Target Date Aug. 7, 2018

Financial news for DRRX dated on 2018-03-07: 44 Biggest Movers From Yesterday

Financial news for DRRX dated on 2018-03-06: Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors

Financial news for DRRX dated on 2018-03-06: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRRX dated on 2018-03-06: Benzinga's Top Upgrades, Downgrades For March 6, 2018

Financial news for DRRX dated on 2018-03-06: H.C. Wainwright Upgrades DURECT to Buy, Announces \$3.50 Price Target

Financial news for DRRX dated on 2018-03-02: Durect Shares Up 8.4% Premarket After Co. Reported Late Thursday Q4 EPS \$0.05, May Not Compare To \$(0.06) Est., Sales \$19.54M May Not Compare To \$3.31M Est.

Financial news for DRRX dated on 2018-02-26: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis

Financial news for DRRX dated on 2018-02-14: DURECT Announces Resubmission of REMOXY ER New Drug Application by its licensee, Pain Therapeutics

Financial news for DRRX dated on 2017-12-13: DURECT Announces the FDA Accepted the NDA for RBP-7000

Financial news for DRRX dated on 2017-11-03: 66 Biggest Movers From Yesterday

Financial news for DRRX dated on 2017-11-02: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for DRRX dated on 2017-11-01: DURECT Reports Q3 EPS \$0.04 vs \$(0.06) Est., Sales \$20.746M

Financial news for DRRX dated on 2017-10-23: 35 Biggest Movers From Friday

Financial news for DRRX dated on 2017-10-20: Mid-Afternoon Market Update: Skechers Jumps On Earnings Beat; Del Taco Shares Slide

Financial news for DRRX dated on 2017-10-20: 32 Stocks Moving In Friday's Mid-Day Session

Financial news for DRRX dated on 2017-10-20: Mid-Day Market Update: Dow Surges Over 100 Points; DURECT Shares Plummet

Financial news for DRRX dated on 2017-10-20: Mid-Morning Market Update: Markets Open Higher; General Electric Earnings Miss Expectations

Financial news for DRRX dated on 2017-10-20: Benzinga's Top Upgrades, Downgrades For October 20, 2017

Financial news for DRRX dated on 2017-10-20: Stifel Nicolaus Downgrades Durect to Hold

Financial news for DRRX dated on 2017-10-20: H.C. Wainwright Downgrades Durect to Neutral

Financial news for DRRX dated on 2017-10-19: UPDATE: DURECT Shares Now Down 54%

Financial news for DRRX dated on 2017-10-19: DURECT Shares Resume Trade, Down 40.6%

Financial news for DRRX dated on 2017-10-19: DURECT Shares To Resume Trade At 6:30 p.m. EDT

Financial news for DRRX dated on 2017-10-19: DURECT Reports Says PERSIST Phase 3 Trial Of POSIMIR Did Not Meet Primary Efficacy Endpoint

Financial news for DRRX dated on 2017-10-19: Durect Shares Halted News Pending

Financial news for DRRX dated on 2017-10-02: Durect Assigns Certain Patents to Indivior for \$17.5M

Financial news for DRRX dated on 2017-08-08: DURECT Reports ORADUR-Methylphenidate ER Capsule Achieved Primary Endpoint In Phase 3 Study In ADHD In Taiwan

Financial news for DRRX dated on 2017-08-03: Zogenix Says on August 1, 2017 Terminated License Agreement Dated July 11, 2011 with Durrect Regarding Relday

Financial news for DRRX dated on 2017-07-12: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for DRRX dated on 2017-07-12: Benzinga's Top Upgrades, Downgrades For July 12, 2017

Financial news for DRRX dated on 2017-07-12: Stifel Nicolaus Upgrades Durect to Buy

Financial news for DRRX dated on 2017-06-19: DURECT Announces Marketing Agreement with Novartis Subsidiary Sandoz is Effective

Financial news for DRRX dated on 2017-06-01: Durect Corp Pops to High of \$1.53 on Volume

Financial news for DRRX dated on 2017-05-11: Durect and Novartis Co. Division Sandoz Sign Development, Commercialization Agreement In U.S. For Posimir

Financial news for DRRX dated on 2017-05-10: DURECT Corp. Reports Q1 EPS \$(0.06), Inline, Sales \$4.567M vs \$3.57M Est.

Financial news for DRRX dated on 2017-05-08: DURECT to get \$20M Payment from a Division of Novartis, Up to \$43M of Development Milestones, Up to \$230M of Sales Milesones

Financial news for DRRX dated on 2017-05-08: Durect Shares Halted, News Pending

Financial news for DRRX dated on 2017-04-24: DURECT Offers Data from Phase 1b Study of DUR-928 in NASH: 'Biomarker analysis provides evidence for a potential therapeutic effect of DUR-928 in NASH'

Financial news for DRRX dated on 2017-03-14: DURECT Corporation Reports Q4 EPS \$(0.06) vs. \$(0.06) Est., Sales \$3.51M vs. \$3.61M Est.

Financial news for DRRX dated on 2017-03-14: Earnings Scheduled For March 14, 2017

Financial news for DRRX dated on 2017-02-28: Benzinga's Top Upgrades, Downgrades For February 28, 2017

Financial news for DRRX dated on 2017-02-28: H.C. Wainwright Initiates Coverage On Durect With Buy, Announces \$3 Price Target

Financial news for DRRX dated on 2017-01-30: DURECT Corp. Offers Update on DUR-928 Development Program, Discusses Phase 1b Trial in Patients with NASH, in Patients with Impaired Kidney Function

Financial news for DRRX dated on 2016-12-22: Watch These 7 Huge Call Purchases In

Thursday Trade

Financial news for DRRX dated on 2016-12-21: Option Alert: DRRX Jul17 2.5 Calls: 2755 @ ASK \$0.30: 2800 traded vs 734 OI: Earnings 2/27 After Close (est) \$1.31 Ref

Financial news for DRRX dated on 2016-11-21: Broadfin Capital Reports 6.14% Passive Stake In Durect Corp in 13G

Financial news for DRRX dated on 2016-11-15: Stifel Healthcare Conference Today

Financial news for DRRX dated on 2016-11-01: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for DRRX dated on 2016-10-31: DURECT Reports Q3 Loss/Share \$0.06 vs Est Loss/Share \$0.07, Revenue \$3.7M vs \$3.72M Est

Financial news for DRRX dated on 2016-10-31: Durect Reports Positive Data From DUR-028 Development Program

Financial news for DRRX dated on 2016-09-27: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for DRRX dated on 2016-09-26: 12 Biggest Mid-Day Losers For Monday

Financial news for DRRX dated on 2016-09-26: DURECT Shares Tumble 32% as Co. Announced Licensee Pain Therapeutics Received FDA CRL for REMOXY ER

Financial news for DRRX dated on 2016-09-26: Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News

Financial news for DRRX dated on 2016-09-26: Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss

Financial news for DRRX dated on 2016-09-26: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for DRRX dated on 2016-09-26: Pain Therapeutics, DURECT Corporation, Array BioPharma to Resume at 7:30 AM ET

Financial news for DRRX dated on 2016-09-22: 25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for DRRX dated on 2016-08-01: DURECT Corp. Reports Q2 EPS \$(0.07) vs. Est. \$(0.06), Rev. \$3.157M vs. Est. \$3.69M

Financial news for DRRX dated on 2016-07-14: Durect Corp Shares Spike to High of \$1.48 on Vol; Move Related to Press Release from Third Party Streetwise Reports

Financial news for DRRX dated on 2016-05-19: DURECT Reports Tentative Date for FDA Panel Meeting Aug. 5, 2016, No Change to PDUFA Date of Sept. 25, '16

Financial news for DRRX dated on 2016-05-05: DURECT Corp Reports Inline Q1 EPS \$(0.06), Sales \$3.608M Vs Est \$4.09M

Financial news for DRRX dated on 2016-04-27: 21 April Fund Ltd Buys 5,500,000 Shares of DURECT @\$1.25/Share -Form 4

Financial news for DRRX dated on 2016-04-26: DURECT Prices 12M Share Offering At \$1.25/Share

Financial news for DRRX dated on 2016-04-25: DURECT Announces Proposed Public Offering of Common Stock, Aggregate Price \$400K

Financial news for DRRX dated on 2016-04-25: Rodman & Renshaw Initiates Coverage on Durect at Buy, Announces \$4.00 PT

Financial news for DRRX dated on 2016-04-07: Durect Corp Filings Says Co Received Letter From FDA Advising Co Make Amendments To PERSIST Trial

Financial news for DRRX dated on 2016-04-07: UPDATE: DURECT Says Change Will Add Time, Cost to Close PERSIST Trial, But Co. Believes Positive Outcome from Trial Design Will Result in Stronger NDA Filing

Financial news for DRRX dated on 2016-04-07: UPDATE: DURECT Says FDA Recommended Incorporation of Standard Bupivacaine HCI as Active Control

Financial news for DRRX dated on 2016-04-07: DURECT Offers Program Update for POSIMIR: Co. Received Letter from FDA Advising Amendments to PERSIST Trial

Financial news for DRRX dated on 2016-03-29: DURECT Reports Licensee, Pain Therapeutics, Resubmitted REMOXY NDA to FDA

Financial news for DRRX dated on 2016-03-16: Chairman Theeuwes Buys 70,000 Shares Of DURECT @\$1.41/Share -Form 4

Financial news for DRRX dated on 2016-03-16: Director Neukermans Buys 18,000 Shares Of DURECT @\$1.39/Share -Form 4

Financial news for DRRX dated on 2016-01-06: DURECT Announces Positive Phase 1 Data for DUR-928

Financial news for DRRX dated on 2015-09-10: Mid-Morning Market Update: Markets Mostly Flat; Krispy Kreme Misses Q2 Estimates

Financial news for DRRX dated on 2015-08-03: Durect Reports Q2 Loss \$0.05 vs Est Loss \$0.06, Sales \$4.441M Vs Est \$55.01M

Financial news for DRRX dated on 2015-06-24: Cantor Analyst: Durect Is Worth \$3/Share, So Buy It

Financial news for DRRX dated on 2015-06-23: DURECT Announces Plans for a New POSIDUR Clinical Trial

Financial news for DRRX dated on 2015-06-15: Mid-Afternoon Market Update: Standard Pacific Rises On Ryland Merger Deal; Micron Shares Slip

Financial news for DRRX dated on 2015-06-12: Mid-Afternoon Market Update: Wingstop Shares Surge in Stock Market Debut; ExOne Shares Tumble

Financial news for DRRX dated on 2015-05-18: DURECT Corp. Reports Positive Results from DUR-928 Multi-Dose Ph

Financial news for DRRX dated on 2015-03-30: DURECT Initiates DUR-928 Multi-Dose Phase 1 Study

Financial news for DRRX dated on 2015-03-26: Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study

Financial news for DRRX dated on 2015-03-10: Durect Corp Director Benito Buys 40,000 Shares @\$1.81/Share -Form 4

Financial news for DRRX dated on 2015-03-03: Morning Market Gainers

Financial news for DRRX dated on 2015-03-03: Cantor Fitzgerald Upgrades Durect to Buy, Raises PT to \$2.00

Financial news for DRRX dated on 2015-03-02: Durect Corp Reports Q4 EPS -\$0.05 Vs Est -\$0.06, Sales \$4.27M Vs Est \$4.32M

Financial news for DRRX dated on 2014-12-16: DURECT Enter Licensing Agreement With Santen Pharmaceutical Co

Financial news for DRRX dated on 2014-11-11: DURECT Offers Update on POSIDUR Program: Certain Scenario Shows Only One Added Test Needed

Financial news for DRRX dated on 2014-10-27: Morning Market Losers

Financial news for DRRX dated on 2014-10-27: Shares of Durect Corp. Plunge Nearly 40% Upon Resumption

Financial news for DRRX dated on 2014-10-27: Durect Corp. Offers Update on REMOXY, POSIDUR Programs: Will Discontinue Deal

Financial news for DRRX dated on 2014-10-27: CORRECTION: Shares of Durect Corp. Halted News Pending

Financial news for DRRX dated on 2014-10-27: Shares of Durect Corp., Pain Therapeutics Halted News Pending

Financial news for DRRX dated on 2014-08-07: Durect Corporation Reports Q2 EPS of \$(0.05), Inline; Revenue of \$4.58M vs \$3.89M Est

Financial news for DRRX dated on 2014-06-26: DURECT Secures \$20M Debt Financing

Financial news for DRRX dated on 2014-05-01: Form 8-K from Durect Shows Co. Expecting to Formally Request Face-to-Face Meeting with FDA Net Week, Expecting One Remoxy Study Concluded in April, Three in June

Financial news for DRRX dated on 2014-05-01: Durect Corporation Reports Q1 EPS of \$(0.03) vs \$(0.05) Est; Revenue of \$6.30M vs \$4.12M Est

Financial news for DRRX dated on 2014-02-27: Durect Corporation Reports Q4 EPS of \$(0.05) vs \$(0.06) Est; Revenue of \$4.30M vs \$2.79M Est

Financial news for DRRX dated on 2014-02-12: Shares of Durect Corp. Resume Trade Down ~35%

Financial news for DRRX dated on 2014-02-12: Durect Corp. Shares to Resume Trade at 5:15PM EST

Financial news for DRRX dated on 2014-02-12: Durect Corp. Receives CRL from FDA on POSIDUR, Says FDA Cannot Approve NDA in Present Form

Financial news for DRRX dated on 2014-02-12: Durect Corp. Halted News Pending

Financial news for DRRX dated on 2014-01-07: Impax & Durect Sign \$63M Deal to Develop, Commercialize Eladur Pain Patch

Financial news for DRRX dated on 2013-12-20: Durect Files \$101M Mixed Securities Shelf

Financial news for DRRX dated on 2013-11-04: Durect Corporation Reports Q3 EPS of \$(0.06), Inline; Revenue of \$2.97M vs \$3.54M Est

Financial news for DRRX dated on 2013-10-22: Pfizer Says Proceeding with Remoxy Development

Financial news for DRRX dated on 2013-10-22: Pain Therapeutics Says Pfizer Elects to Continue Development of REMOXY(R)

Financial news for DRRX dated on 2013-09-10: UPDATE: FDA Will Be Holding an Official Briefing at 12:45PM EDT to Discuss an Undisclosed Topic

Financial news for DRRX dated on 2013-09-10: FDA Traders Considering Admin. Updates Labels on Long-Acting Painkillers

Financial news for DRRX dated on 2013-08-16: Market Wrap for Friday, August 16: Pullback In Equities Continues To Close Week

Financial news for DRRX dated on 2013-08-05: UPDATE: Durect Provides Update of Programs

Financial news for DRRX dated on 2013-08-05: Durect Corporation Reports Q2 EPS of \$(0.05), Inline; Revenue of \$3.92M vs \$3.42M Est

Financial news for DRRX dated on 2013-06-20: DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDUR(r) (SABER(r)-Bupivacaine)

Financial news for DRRX dated on 2013-05-10: Mid-Morning Market Update: Gold Futures See Sharp Decline, Ubiquity Networks Reports Growth for Second Straight Quarter

Financial news for DRRX dated on 2013-05-10: Morning Market Losers

Financial news for DRRX dated on 2013-05-02: Durect Corporation Reports Q1 EPS of \$(0.05) vs \$(0.07) Est; Revenue of \$4.20M vs \$3.87M Est

Financial news for DRRX dated on 2013-04-30: Traders Attributing Strength in Pain Therapeutics, Durect to Comments from Pfizer Exec on Call Co. Optimistic About Prospects for Improved Tamper-Resistant Pain Drugs

Financial news for DRRX dated on 2013-04-30: UPDATE: Pain Therapeutics Shares Now Up 35%, Durect Shares Up 47%

Financial news for DRRX dated on 2013-04-30: Durect Corp. Shares Resume Trade, Now Up 32%

Financial news for DRRX dated on 2013-04-30: Durect Halted on Circuit Breaker, Now Up 32%

Financial news for DRRX dated on 2013-04-16: DURECT Announces Submission of NDA for POSIDUR

Financial news for DRRX dated on 2013-03-25: Stifel Nicolaus Initiates Coverage on Durect Corporation at Buy, Announces \$3.00 PT

Financial news for DRRX dated on 2013-02-28: Durect Corporation Reports Q4 EPS of \$(0.06) vs \$(0.05) Est

Financial news for DRRX dated on 2013-01-03: Zogenix Announces Positive Relday Phase

1 Clinical Trial Results

Financial news for DRRX dated on 2012-12-06: From Earlier: Durect Prices 14M Shares at \$0.90/Share

Financial news for DRRX dated on 2012-12-06: From Earlier: Durect Prices 14M Shares at \$0.90/Share

Financial news for DRRX dated on 2012-12-06: DURECT Prices 14M Share Offering at \$0.90 per Share

Financial news for DRRX dated on 2012-12-06: DURECT Prices 14M Share Offering at \$0.90/Share

Financial news for DRRX dated on 2012-11-05: Durect Reports Q3 EPS \$-0.05 vs \$-0.05 Est; Revenues \$3.8M vs \$5.49M Est

Financial news for DRRX dated on 2012-11-01: CK Cooper Downgrades Durect from Buy to Hold

Financial news for DRRX dated on 2012-11-01: Durect Shares Have Resumed Following Circuit Breaker, Stock Down 39%

Financial news for DRRX dated on 2012-11-01: Durect Halted Again on Circuit Breaker, Now Down Just 14%

Financial news for DRRX dated on 2012-11-01: Durect Shares Resume

Financial news for DRRX dated on 2012-11-01: Durect Shares Halted on Circuit Breaker, Now Down 40%

Financial news for DRRX dated on 2012-08-17: Benzinga's Top Initiations

Financial news for DRRX dated on 2012-08-17: UPDATE: CK Cooper & Company Initiates DURECT Corporation at Buy on Potential Drug Approval

Financial news for DRRX dated on 2012-08-17: C.K. Cooper & Company Initiates Coverage Durect at Buy, Announces PT of \$3

Financial news for DRRX dated on 2012-08-06: DURECT Announces Intent to Submit NDA for POSIDUR(tm) for Post-Operative Analgesia

Financial news for DRRX dated on 2012-08-06: Durect Reports Q2 EPS \$0.00 vs \$-0.05 Est

Financial news for DRRX dated on 2012-07-21: Benzinga's Microcap Movers for Friday July 20, 2012

Financial news for DRRX dated on 2012-05-30: Benzinga's Microcap Movers for Wednesday May 30, 2012

Financial news for DRRX dated on 2012-05-30: Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)

Financial news for DRRX dated on 2012-05-03: Pain Therapeutics Announces Four U.S. Patents Issued for REMOXY

Financial news for DRRX dated on 2012-05-03: DURECT Announces Issuance of U.S. Patents Covering ORADUR Technology

Financial news for DRRX dated on 2012-03-29: DURECT Receives Back U.S. and Canadian Product Rights to POSIDUR(tm)

Financial news for DRRX dated on 2012-03-01: Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT

Financial news for DRRX dated on 2012-03-01: Durect Says Pfizer Ending License Pact

Financial news for DRRX dated on 2012-01-30: DURECT Receives Back European Product Rights to POSIDUR

Financial news for DRRX dated on 2012-01-05: Durect Corporation Resumes Trading

Financial news for DRRX dated on 2012-01-05: Durect Corporation Resumes Trading

Financial news for DRRX dated on 2012-01-05: PREVIEW: Durect to Resume Trading at 4:45pm

Financial news for DRRX dated on 2012-01-05: DURECT Announces Top-line Data from

BESST; Did Not Reach Statistical Significance

Financial news for DRRX dated on 2011-09-06: DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR

Financial news for DRRX dated on 2011-07-12: Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro Delivery System and DURECT's SABER Depot Technology

Financial news for DRRX dated on 2011-06-27: Piper Jaffray Maintains OW Rating and \$4 PT on Durect

Financial news for DRRX dated on 2011-06-24: Top Percentage Gainers and Losers as of 2pm 6/24/11

Financial news for DRRX dated on 2011-06-24: Top Percentage Gainers and Losers as of 12:15pm 6/24/11

Financial news for DRRX dated on 2011-06-24: Durect Corporation and Pain Therapeutics Resume Trading

Financial news for DRRX dated on 2011-06-24: Benzinga's Top Pre-Market NASDAQ Losers

Financial news for DRRX dated on 2011-06-24: PREVIEW: Durect Corporation and Pain Therapeutics to Resume at 8:30 a.m. ET

Financial news for DRRX dated on 2011-06-24: Durect Corporation Halted, Pending News

Financial news for DRRX dated on 2011-06-24: DURECT Corporation Down Nearly 20% Pre-Market on FDA Rejection

Financial news for DRRX dated on 2011-06-22: FDA PDUFA Dates Scheduled for Tomorrow: LCI, DRRX, and PITE

Financial news for DRRX dated on 2011-06-02: DURECT Announces Resignation of Chief Medical Officer

Financial news for DRRX dated on 2011-05-06: Piper Jaffray Overweight On DURECT Corporation (DRRX)

Financial news for DRRX dated on 2011-04-12: Top Percentage Gainers And Losers As Of 2 p.m. 4/12/2011 (CYH, THC, IDIX, BAC, SKH, JPM, BIO, REDF, DEER, THC, CYTX, CCRT, WMS, EXTR, LFT, SB, DRRX, BRNC, MCRL)

Financial news for DRRX dated on 2011-04-12: Top Percentage Gainers And Losers As Of 12 p.m. 4/12/2011 (SKH, JPM, CYH, THC, SIFY, TIBX, HPQ, IDIX, BAC, CCRT, WMS, EXTR, SB, PSTR, GLUU, UAL, GIL, DRRX, SGI, AIB)

Financial news for DRRX dated on 2011-04-11: DURECT Announces ELADUR Phase II Study Results in Chronic Low Back Pain

Financial news for DRRX dated on 2011-04-11: DURECT Announces ELADUR Phase II Study Results in Chronic Low Back Pain

Financial news for DRRX dated on 2011-03-02: DURECT Corporation Reports Q4 EPS of \$(0.06)

Financial news for DRRX dated on 2011-02-08: DURECT Announces Launch of First FDA Approved SABER Injectable Peptide Product

Financial news for DRRX dated on 2011-02-02: Hospira Misses; 2011 View Weak - Analyst Blog

Financial news for DRRX dated on 2011-02-02: Hospira Misses; 2011 View Weak - Analyst Blog

Financial news for DRRX dated on 2011-01-27: DURECT Announces REMOXY New Drug Application Accepted by the FDA

Financial news for DRRX dated on 2011-01-24: Pfizer Extends King Tender Offer - Analyst Blog

Financial news for DRRX dated on 2011-01-24: Pfizer Extends King Tender Offer - Analyst Blog

Financial news for DRRX dated on 2010-12-29: King Pharma Resubmits Remoxy NDA - Analyst Blog

Financial news for DRRX dated on 2010-12-29: King Pharma Resubmits Remoxy NDA -

Analyst Blog

Financial news for DRRX dated on 2010-12-27: A Peek Into The Market Before The Trading Starts

Financial news for DRRX dated on 2010-12-27: REMOXY Drug Application Resubmitted

Financial news for DRRX dated on 2010-11-03: DURECT Corporation Announces Third Quarter 2010 Financial Results

Financial news for DRRX dated on 2010-08-05: Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX)

Financial news for DRRX dated on 2010-08-05: Jeffries Keeps Its Buy Rating On DRRX

Financial news for DRRX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?